Search for: "CELGENE"
Results 81 - 100
of 183
Sort by Relevance
|
Sort by Date
27 Jul 2017, 2:42 pm
Celgene Corp., a New Jersey pharmaceutical manufacturer, has agreed to pay $280 million to settle a False Claims Act lawsuit… The post Pharmaceutical Manufacturer Agrees to Pay $280 Million to Settle Healthcare Whistleblower Lawsuit appeared first on TZ Legal - Fraud Fighters. [read post]
27 Jul 2017, 10:37 am
” The allegations against Celgene were brought to court by healthcare whistleblower Beverly Brown, who had been employed as a sales manager by Celgene. [read post]
27 Jul 2017, 10:37 am
” The allegations against Celgene were brought to court by healthcare whistleblower Beverly Brown, who had been employed as a sales manager by Celgene. [read post]
27 Jul 2017, 5:28 am
The settlement resolves a lawsuit that alleged Celgene violated the federal False Claims Act by submitting false claims to Medicare. [read post]
27 Jul 2017, 5:28 am
The settlement resolves a lawsuit that alleged Celgene violated the federal False Claims Act by submitting false claims to Medicare. [read post]
24 Jul 2017, 3:46 pm
Celgene has agreed to pay $280 million to settle allegations that the company marketed two of its drugs for off-label uses. [read post]
24 Jul 2017, 3:46 pm
Celgene has agreed to pay $280 million to settle allegations that the company marketed two of its drugs for off-label uses. [read post]
14 Apr 2017, 3:02 am
Here’s the 113-page Wells Fargo board report – and here’s the news: – NY Times “Wells Fargo to Claw Back $75 Million From 2 Former Executives” – USA Today’s “Wells Fargo clawing back $75.3 million more from former execs in fake accounts scandal” – WSJ’s “Wells Fargo Claws Back Millions From CEO After Scandal” – Fortune’s “How Wells Fargo’s Carrie Tolstedt Went from Fortune Most Powerful Woman… [read post]
10 Apr 2017, 5:00 am
The staff said it was unable to concur with Celgene’s view that the proposal could be omitted on any of the three bases. [read post]
10 Feb 2017, 9:46 pm
The Supreme Court decision was almost immediately cited by an Australian Patent Hearing Officer, who found that a claimed method for commercialising inventions does not constitute patentable subject matter under the Australian ‘manner of manufacture’ test: Invention Pathways Pty Ltd [2010] APO 10.The Invention Pathways decision resulted in an official change to Australian Patent Office practice whereby a claimed invention, to be patent-eligible, would not only need to involve a… [read post]
5 Jun 2016, 4:00 am
Dans Celgene Corp. c. [read post]
18 Jan 2016, 6:34 am
Soon-Shiong announced that a consortium of drug companies, including Southern California biotech giant Amgen and global pharma company Celgene, would join in large-scale testing of their anti-cancer therapies in hopes of finding mixes or cocktails tailored to and effective against specific cancers. [read post]
4 Jan 2016, 10:56 am
Revlimid represented 65% of Celgene's product sales in 2014. [read post]
24 Oct 2015, 11:19 am
Celgene is up since Hayman filed IPR challenges against in April and May. [read post]
12 Oct 2015, 12:46 pm
The first bit of good news for Bass came with respect to his IPR petition against Celgene Corporation. [read post]
12 Oct 2015, 12:46 pm
The first bit of good news for Bass came with respect to his IPR petition against Celgene Corporation. [read post]
11 Oct 2015, 9:38 pm
October 12, 2015 - "Hedge Fund IPR Challenges to Pharma Patents: Latest Developments and Strategies to Strengthen Patents -- Lessons From PTAB Denial of Acorda Therapeutics IPR, Celgene's Sanctions Motion, and More" (Strafford) - 1:00 to 2:30 pm (EDT) October 13, 2015 - Post-Grant Practice Roundtable Discussion (George Washington Law School) - George Washington University Law School October 13, 2015 - Patent Quality Chat webinar series (U.S. [read post]
27 Sep 2015, 10:00 pm
Celgene Corp. had filed motions for sanctions in IPRs brought against its patents relating to Thalomid® (thalidomide) and Revlamid®... [read post]
27 Sep 2015, 10:00 pm
Celgene Corp. had filed motions for sanctions in IPRs brought against its patents relating to Thalomid® (thalidomide) and Revlamid®... [read post]
26 Sep 2015, 9:05 pm
Strafford will be offering a webinar/teleconference entitled "Hedge Fund IPR Challenges to Pharma Patents: Latest Developments and Strategies to Strengthen Patents -- Lessons From PTAB Denial of Acorda Therapeutics IPR, Celgene's Sanctions Motion, and More" on October 12, 2015 from 1:00 to 2:30 pm (EDT). [read post]
